Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | CEO, President & Director | 940.38k | -- | 1967 |
| Dr. Eran Ophir Ph.D. | Chief Scientific Officer | 356.81k | -- | 1978 |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Technology Innovation | 355.84k | -- | 1968 |
| Dr. Pierre Ferre Ph.D. | Vice President of Preclinical Development | 449.96k | -- | 1977 |
| Mr. David Silberman CPA | Chief Financial Officer | -- | -- | 1984 |
| Ms. Yvonne Naughton | Head of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Eran Ben Dor | General Counsel & Corporate Secretary | -- | -- | -- |
| Ms. Dorit Amitay | Vice President of Human Resources | -- | -- | 1968 |
| Dr. Yaron Turpaz M.B.A., Ph.D. | Senior VP & Senior Advisor of Data and Informatics Solutions | -- | -- | 1971 |
| Rivka Schwartz | Vice President Research and Discovery | -- | -- | -- |
Compugen Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 68
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Corporate Governance
Upcoming Events
March 3, 2025 at 1:30 PM UTC - March 7, 2025 at 1:30 PM UTC
Compugen Ltd. Earnings Date